Biomednewsbreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding To Advance Age-Reversal Therapies

(MENAFN- Investor Brand Network) Telomir Pharmaceuticals (NASDAQ: TELO)
has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir's strategy. The funding supports Telomir's innovative pipeline, led by its breakthrough compound, Telomir-1, which has demonstrated preclinical efficacy in reversing age-related conditions, including Type 2 diabetes, by addressing root causes like oxidative stress and telomere shortening. Telomir is also advancing research in Alzheimer's, cancer, osteoarthritis, and Wilson Disease, positioning itself as a pioneer in age-reversal and chronic disease therapies.

To view the full press release, visit

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a preclinical stage pharmaceutical company seeking to lead development in longevity science in both humans and animals. The company is focused on the development of
Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. For more information about the company, visit the website
.

NOTE TO INVESTORS:
The latest news and updates relating to TELO are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN12122024000224011066ID1108987421